Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might be. Then it is not very good. They say there will be a press conference call, with the new name of their product. Now all dissappear!
Yes, want to get the facts.
No prove of the extract effect, only "might be". It is far from enough. What other good news we can expect for?
Going nowhere at the moment. When the action would come?
Not only the name. The key is they can not prove before extract treatment, it is a BCC.
I printed and looked the breaking news again. This could not prove anything that the CBIS extracts can cure any case of cancer! We need solid prove, at least in some or one case, but this is not! Any MD can see that easily.
Where are other eggs? This is not an egg even. The only hope is that they do have more real eggs. But when and where? Without those, where can it go? 0.075 would be a strong resistance in a short term. It may come down again. Only hoping they can show sth real.
Why no one can answer this question, the date there is 03.03.2011?
And no evidence that this case is indeed benefits from CBIS!
That is the main problem here. Nothing much excited. Not like the bank merge news! It is just too too too weak!
It is not clear and the date is March 03. And there are no details!
How mayn M we have on this board? I guess 3-4 M?
I really hope they can file it today.
For the quarter ended December 31, 2010, Nephros recognized net product revenues of approximately $517,000 compared with approximately $792,000 in the corresponding period of 2009, a decrease of $275,000 or 35%. The $275,000 decrease in net product revenues is primarily due to a decrease of approximately $216,000 in billings related to our contract with the Office of U.S. Naval Research during the three months ended December 31, 2010 compared to the three months ended December 31, 2009.
Everything is depending on the news now. News is the fuel for the leaky ship to the next station. Maybe not much time left and the market is still waiting.
What and where is the MM took a number of 0.062?
For the gap, it will close for sure within a month.
To market it could be bad. The 0.062, 0.06 and now 0.0575 and 0.0452 bids are gone.
To me it is not bad but also not exciting. This fish is still really small. He needs to eat more. And we have to wait two more years?
Yes, insiders are selling hard at 0.03!
http://www.insidercow.com/history/company.jsp?company=gnta&B1=Search!
Hope news will come out 1 hour before close, like last time.
"Due to financial constraints and regulatory burdens, 2010 was a challenging year for Nephros. Despite these challenges, we have continued to lay the foundation for success," said Dr. Paul Mieyal, Acting CEO of Nephros. "With our recently completed financing activities, Nephros is better positioned in 2011 to take advantage of the attractive opportunities which continue to evolve for the Company's products. We are looking forward to an exciting year with continued efforts to reward the Company's shareholders for their support."
During the twelve months ended December 31, 2010, we were granted six new patents.
FDA meeting on April 20, 2011
...U.S. Army is waiting for more money to buy UF-40 ultrafilter.
Nephros Reports 2010 Fourth Quarter and Full Year Financial Results
March 29, 2011 5:00 PM ET
Nephros Reports 2010 Fourth Quarter and Full Year Financial Results
PR Newswire
RIVER EDGE, N.J., March 29, 2011
RIVER EDGE, N.J., March 29, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPHD), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, announced today financial results for the three months and full year ended December 31, 2010.
2010 Highlights
* Increased revenues by 10.4% to approximately $2,938,000 from prior year period
* Increased gross margin by 22% to approximately $1,122,000 from prior year period
* Reduced loss from operations by approximately $517,000 or 21% from prior year period
* Signed development agreement with STERIS Corporation
* Announced that AmeriWater adopted the Nephros DSU as a standard component of its portable reverse osmosis water treatment systems for dialysis
* Six new patents granted
"Due to financial constraints and regulatory burdens, 2010 was a challenging year for Nephros. Despite these challenges, we have continued to lay the foundation for success," said Dr. Paul Mieyal, Acting CEO of Nephros. "With our recently completed financing activities, Nephros is better positioned in 2011 to take advantage of the attractive opportunities which continue to evolve for the Company's products. We are looking forward to an exciting year with continued efforts to reward the Company's shareholders for their support."
Financial Performance for the Year Ended December 31, 2010
Revenues for the twelve months ended December 31, 2010 were approximately $2,938,000 compared to approximately $2,661,000 in the corresponding period of 2009, an increase of approximately 10%. The Company's net loss was approximately $1,933,000 or $0.93 per basic and diluted loss per common share for the twelve months ended December 31, 2010 compared with approximately $2,026,000 or $1.02 per basic and diluted loss per common share for the corresponding period of 2009. Loss from operations for the twelve months ended December 31, 2010 was approximately $1,889,000 compared to approximately $2,406,000 in the corresponding period of 2009. The $517,000 reduction in operating loss resulted from: an increase of approximately $205,000 in gross profit due to increased revenue; a reduction in depreciation expense of approximately $102,000; and a reduction in selling, general and administrative expenses of approximately $292,000; all of which was partially offset by a $82,000 increase in research and development expenses.
As of December 31, 2010, Nephros had cash and cash equivalents of approximately $240,000. As previously announced in March 2011, Nephros completed a shareholder rights offering and private placement which collectively raised approximately $3.2 million in gross proceeds. After repayment of the company's outstanding Note, fees, and expenses, net cash proceeds to the Company were approximately $2.3 million.
Financial Performance for the Fourth Quarter Ended December 31, 2010
For the quarter ended December 31, 2010, Nephros recognized net product revenues of approximately $517,000 compared with approximately $792,000 in the corresponding period of 2009, a decrease of $275,000 or 35%. The $275,000 decrease in net product revenues is primarily due to a decrease of approximately $216,000 in billings related to our contract with the Office of U.S. Naval Research during the three months ended December 31, 2010 compared to the three months ended December 31, 2009. Revenue from sales of our MD filters in our Target European Market was approximately $104,000 lower in the three months ended December 31, 2010 compared to the same period in 2009. Approximately $84,000 of the European revenue decrease was due to less units sold plus an additional decrease of approximately $20,000 due to foreign currency exchange rate fluctuation. Unit sales in Europe decreased approximately 22% for the three months ended December 31, 2010 compared to the same period in 2009. These decreases were partially offset by increased revenue of approximately $45,000 in sales of our DSU in the United States for the three months ended December 31, 2010 compared to the same period in 2009. Approximately $33,000 of the increased DSU sales was related to the recognition of revenue previously deferred, associated with the development agreement with STERIS Corporation.
Operating expenses for the three months ended December 31, 2010 were approximately $751,000 compared with approximately $828,000 in the corresponding period of 2009. The decrease of approximately $77,000 is related, in part, to the reduction in depreciation expense of $10,000 or 24% in the fourth quarter of 2010 compared to the same period in 2009. Selling, general and administrative expenses were approximately $102,000 or 14% less in the fourth quarter of 2010 compared to the same period in 2009. The decrease is primarily due to a decrease in personnel related expenses of approximately $202,000 during the three months ended December 31, 2010 compared to the three months ended December 31, 2009. This decrease was partially offset by increased legal costs of approximately $110,000 during the three months ended December 31, 2010, related to our recently completed rights offering, compared to the three months ended December 31, 2009.
Research and development expenses increased by approximately $35,000 in the fourth quarter of 2010 compared to the same period in 2009. Approximately $29,000 of the increase was wages primarily due to personnel working on research projects other than the contract with the Office of U.S. Naval Research. The remaining $6,000 increase is due to increased spending on machine development work during the three months ended December 31, 2010 compared to the same period in 2009.
Nephros's net loss was approximately $665,000 or $0.32 per basic and diluted common share for the fourth quarter of 2010 versus a net loss of approximately $483,000 or $0.25 per basic and diluted common share in the fourth quarter of 2009. Nephros's net loss increased $182,000 in the current quarter primarily due to the approximately $75,000 or 14% reduction in loss from operations in the fourth quarter of 2010 compared to the same period in 2009. This reduction in loss from operations was offset by an approximately $107,000 increase in other expenses. Other expense of approximately $15,000 in interest expense and $50,000 of debt issuance costs were incurred during the three months ended December 31, 2010. Other income of approximately $41,000 was realized during the three months ended December 31, 2009.
During the twelve months ended December 31, 2010, we were granted six new patents. In the U.S., we were issued patent #7,775,375 for our Dual Stage Ultrafilter (DSU). In Canada, we were issued patents #2,431,431 for a Multistage Hemodiafiltration/Hemofiltration Method and Apparatus which forms the basis of our mid-dilution technology and patent #2,437,090 for a Method and Apparatus for a Hemodiafiltration Delivery Module which covers our H2H Hemodiafiltration device. In Japan, we were issued patents #4623909 and #4436569 for a Sterile Fluid Filtration Cartridge and a Non-Isomotic Diafiltration Sytem and Method, respectively. And in Europe, European patent #134787821 was granted for our OLpur MD HDF Filter under the title, Dual Stage Hemodiafiltration cartridge, and whereby individual patents were granted in the countries of Germany, France, Italy, Spain, United Kingdom, Netherlands, Sweden, and Hong Kong.
Outlook for 2011
Nephros is projecting an increase in aggregate gross sales of mid-dilution (MD) dialyzers in Europe and Canada of approximately 20% as compared to 2010 on a units sold basis.
Nephros has a meeting scheduled with the FDA for April 20, 2011 to discuss a proposal for submission of a new 510(k) application for its on-line HDF system. Depending on the results of that meeting, Nephros currently anticipates proceeding with the submission of a new 510(k) application for approval of its hemodiafiltration system in the U.S. by the third quarter of 2011 which would be subject to the FDA's standard 90-day review period. In the event that the April 20th FDA meeting results in a materially different expectation, Nephros will inform its shareholders of the revised outlook. Nephros believes that, if approved, its technology would be the first FDA-approved on-line HDF therapy available in the U.S.
The Association for the Advancement of Medical Instruments' (AAMI) adoption of more stringent water purity standards for dialysis applications as well as observational studies showing a significant reduction in required erythropoietin dosing when the Nephros DSU is utilized during dialysis therapy has significantly increased interest in the product. Nephros has filed a special 510(k) application for its SSU and MSU filters to enable these products to be used in dialysis applications. Nephros expects to realize accelerating product sales to the U.S. dialysis market as a combined result of these driving factors. Nephros also expects to realize initial sales of DSU products to dialysis markets outside the U.S. in 2011.
Nephros has introduced product line extensions for the hospital infection control market which include a more durable filter design to withstand the higher pressures of hospital plumbing, filter covers to improve the aesthetics of the filters in hospital showers, and the SafeSpout as a convenient endpoint filter to address acute outbreak scenarios. Nephros is investigating a range of additional commercial, industrial, and military opportunities for its DSU technology.
During 2011, Nephros plans to increase its sales and marketing activities in an effort to significantly expand the Company's market presence in the dialysis and infection control arenas. To this end, Nephros has engaged Zwolinski Management Consulting to facilitate and reinforce these activities.
During 2010, Nephros completed the initial milestone under the joint collaboration agreement with STERIS Corporation and expects to complete the final milestones under the agreement by the end of the third quarter of 2011. The remaining milestones, if met, would result in aggregate payments to Nephros of $60,000.
In response to a Request For Information (RFI) from the U.S. Army, Nephros submitted its UF-40 ultrafilter for consideration as part of the standard issue hydration pack for soldiers in the field. Nephros has been informed by the U.S. Army Public Health Command that its UF-40 filter has been validated to meet the military's NSF P248 standard for emergency military operations as a microbiological water purifier. Nephros believes that its UF-40 filter is the only stand-alone filter to date to have met the performance criteria of the NSF P248 standard without secondary disinfection steps. The Army has not to date issued a Request For Proposal (RFP), and Nephros has no information regarding when or if an RFP applicable to the UF-40 ultrafilter may be put forth by the U.S. Army.
Nephros Reports 2010 Fourth Quarter and Full Year Financial Results
Do you talk to Mark recently? The date for Q-report is getting near and when will the Pr?
News!!!!!
is coming this week?
When should we see the Q-report? Another 50% increase?
Today's open: 0.071; close 0.070
Still 0.07, the last trade.
That is a very good news! And the volume is arising. Hopefully something will happen soon.
Looks like it will come down a bit finally. No interests at all locking in the area of 0.073 to 0.08. Let us have some funs!
That is 12700 shares at price of 0.005 before RS, WTF!
Look at the volume! There is nearly nothing!
This guy has been staying at 0.074 to 0.08 for a whole week or more. There will be a changing time.
No one is selling now. Do not take the 0.062 price! Because we can fly higher.
Nearly no trading till now! It maybe a big break out near!
I mean RS. But I do not think there will be any good news, baybe we have to wait 5 years to see something.
March 15, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that as previously announced, Nephros, Inc. effected a one-for-twenty reverse stock split at 5:00 p.m. on March 11, 2011. Nephros has been advised by the Financial Industry Regulatory Authority (FINRA) that FINRA has established Thursday, March 17 as the day on which the stock will begin trading on a split-adjusted basis on the OTC Bulletin Board. Nephros shares will continue to trade under the symbol "NEPH." but will contain a "D" suffix for twenty business days to indicate the reverse stock-split.
From my account I can trade the new stocks with current PPS! So where is the PS ?!
10th Annual SEAA Conference
March 21 - 23, 2011
Come talk to the
Wireless Transaction Specialists
Hyatt Regency Bonaventure Hyatt
Conference Center and Resort
250 Racquet Club Road
Weston, FL 33326
It's time for the Southease Acquirers' Association Annual Seminar at the beautiful Hyatt Regency, Bonaventure in Weston, Florida! This is the perfect opportunity to see the latest and greatest in the payments and transactions industry...especially with RedFin Network, one of the most powerful and robust payment gateways available today, and your Wireless Transaction Specialists.
We are now setting appointments to showcase all the products and services that RedFin Network offers, including the new 15" WiFi enabled HioPOS All-in-One Point of Sale Solution, and new information about the P25-M for the iPhone.
Contact Bill Paul to set your appointment and reserve your place today...time slots are limited, and the SEAA 2011 Conference is right around the corner, so don't delay!
Why so quiet today? What is your plan for this week?
Why it is still 0.02s and not 40 cents?! Anyone knows?
I guess 0.079
Sure. I am wondering how do you find them in a good time?? In CBIS in 24.01 and in that in 03.02. How do you find them? I got to know CBIS from SFNL board a few days ago. I missed the best time and in later. I do think it is still good. However the better entry time would be better!
How do you find them?